Company intelligence / Profile preview

Kairen

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Kairen is a clinical-stage biotechnology company specializing in the development of next-generation RNA interference (RNAi) therapeutics. Based in Suzhou, China, the company leverages its proprietary small interfering RNA (siRNA) delivery platform to address unmet medical needs in chronic and metabolic diseases. Its lead candidate, KR-001, is a long-acting siRNA targeting PCSK9 for the treatment of hyperlipidemia and is currently undergoing Phase 1 clinical trials. Kairen's pipeline also includes programs targeting ANGPTL3 and other validated metabolic targets, aiming to provide more effective and convenient treatment options for global patients.

Therapeutic areas: CardiovascularMetabolic Disorders
Modalities: Small interfering RNARNA therapy
Industry: Biotech

Beyond the preview

Go deeper on Kairen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kairen.

Explore the full profile